| Literature DB >> 31121608 |
Shadi Tabibian1, Yavar Shiravand2, Mahmood Shams3, Majid Safa1, Mohammad Saeed Gholami1, Farshad Heydari1, Abbas Ahmadi4, Jamal Rashidpanah5, Akbar Dorgalaleh1.
Abstract
Coagulation factor (F) V is a glycoprotein that plays an essential role in the formation of the prothrombinase complex, which is critical for progressing clot formation. FV deficiency is a rare bleeding disorder with an estimated incidence of one per 1 million in the general population. The disorder is manifested with a wide array of clinical bleeding events. The most common bleeding features of FV deficiency are mucosal bleedings. Life-threatening manifestations are rarely seen in this disorder. FV deficiency is diagnosed using routine coagulation tests and FV activity assay. A wide spectrum of mutations including missense, nonsense, and frameshift is observed throughout the F5 gene. Although fresh frozen plasma is the dominant therapeutic choice, a newly introduced plasma-derived FV concentrate was found effective in in vitro correction of prothrombin time, activated partial thromboplastin time, and thrombin generation parameters in severe FV deficiency and should provide more targeted treatment for patients with FV deficiency in the future. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31121608 DOI: 10.1055/s-0039-1687906
Source DB: PubMed Journal: Semin Thromb Hemost ISSN: 0094-6176 Impact factor: 4.180